Keywords
Last Name

Kevin Outterson, JD, LLM

TitleProfessor of Law and N. Neal Pike Scholar
InstitutionBoston University School of Law
DepartmentHealth and Disability Law
Address765 Commonwealth Ave
Boston MA
Other Positions
TitleAssociate Professor
InstitutionBoston University School of Public Health
DepartmentHealth Law, Policy & Management

TitleExecutive Director
InstitutionBoston University School of Law
DepartmentCombating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)

 Research Expertise & Professional Interests
Research interests in pharmaceutical innovation, including the law & economics of antimicrobial resistance.

 Publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Deak D, Powers JH, Outterson K, Kesselheim AS. The Fight Against Multidrug-Resistant Bacteria. Ann Intern Med. 2017 Jan 03; 166(1):79. PMID: 28030672.
    View in: PubMed
  2. Outterson K, McDonnell A. Antimicrobial Resistance: The Authors Reply. Health Aff (Millwood). 2016 Oct 01; 35(10):1936. PMID: 27702975.
    View in: PubMed
  3. Outterson K, Rex JH, Jinks T, Jackson P, Hallinan J, Karp S, Hung DT, Franceschi F, Merkeley T, Houchens C, Dixon DM, Kurilla MG, Aurigemma R, Larsen J. Accelerating global innovation to address antibacterial resistance: introducing CARB-X. Nat Rev Drug Discov. 2016 09; 15(9):589-90. PMID: 27469032.
    View in: PubMed
  4. Outterson K, Gopinathan U, Clift C, So AD, Morel CM, Røttingen JA. Delinking Investment in Antibiotic Research and Development from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality. PLoS Med. 2016 Jun; 13(6):e1002043. PMID: 27299990.
    View in: PubMed
  5. Deak D, Outterson K, Powers JH, Kesselheim AS. Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug Administration-Approved Antibiotics, 2010-2015. Ann Intern Med. 2016 Sep 06; 165(5):363-72. PMID: 27239977.
    View in: PubMed
  6. Outterson K, McDonnell A. Funding Antibiotic Innovation With Vouchers: Recommendations On How To Strengthen A Flawed Incentive Policy. Health Aff (Millwood). 2016 May 01; 35(5):784-90. PMID: 27140983.
    View in: PubMed
  7. Rex JH, Outterson K. Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach. Lancet Infect Dis. 2016 Apr; 16(4):500-5. PMID: 27036356.
    View in: PubMed
  8. Årdal C, Outterson K, Hoffman SJ, Ghafur A, Sharland M, Ranganathan N, Smith R, Zorzet A, Cohn J, Pittet D, Daulaire N, Morel C, Rizvi Z, Balasegaram M, Dar OA, Heymann DL, Holmes AH, Moore LS, Laxminarayan R, Mendelson M, Røttingen JA. International cooperation to improve access to and sustain effectiveness of antimicrobials. Lancet. 2016 Jan 16; 387(10015):296-307. PMID: 26603920.
    View in: PubMed
  9. Outterson K, Powers JH, Daniel GW, McClellan MB. Repairing the broken market for antibiotic innovation. Health Aff (Millwood). 2015 Feb; 34(2):277-85. PMID: 25646108.
    View in: PubMed
  10. Hoffman SJ, Outterson K, Røttingen JA, Cars O, Clift C, Rizvi Z, Rotberg F, Tomson G, Zorzet A. An international legal framework to address antimicrobial resistance. Bull World Health Organ. 2015 Feb 01; 93(2):66. PMID: 25883395.
    View in: PubMed
  11. Hoffman SJ, Outterson K. INTRODUCTION: What Will It Take to Address the Global Threat of Antibiotic Resistance? J Law Med Ethics. 2015; 43 Suppl 3:6-11. PMID: 26243236.
    View in: PubMed
  12. Hoffman SJ, Outterson K. What Will It Take to Address the Global Threat of Antibiotic Resistance? J Law Med Ethics. 2015; 43(2):363-8. PMID: 26242959.
    View in: PubMed
  13. Outterson K. Clinical trial transparency--antidote to weaker off-label-promotion rules? N Engl J Med. 2014 Jul 3; 371(1):1-3. PMID: 24988551.
    View in: PubMed
  14. Outterson K. The Drug Quality and Security Act--mind the gaps. N Engl J Med. 2014 Jan 9; 370(2):97-9. PMID: 24369048.
    View in: PubMed
  15. Outterson K, Powers JH, Seoane-Vazquez E, Rodriguez-Monguio R, Kesselheim AS. Approval and withdrawal of new antibiotics and other antiinfectives in the U.S., 1980-2009. J Law Med Ethics. 2013; 41(3):688-96. PMID: 24088160.
    View in: PubMed
  16. Outterson K. Regulating compounding pharmacies after NECC. N Engl J Med. 2012 Nov 22; 367(21):1969-72. PMID: 23134357.
    View in: PubMed
  17. Outterson K. Punishing health care fraud--is the GSK settlement sufficient? N Engl J Med. 2012 Sep 20; 367(12):1082-5. PMID: 22970920.
    View in: PubMed
  18. Outterson K. Smoking and the First Amendment. N Engl J Med. 2011 Dec 22; 365(25):2351-3. PMID: 22149735.
    View in: PubMed
  19. Outterson K. Higher First Amendment hurdles for public health regulation. N Engl J Med. 2011 Aug 18; 365(7):e13. PMID: 21812665.
    View in: PubMed
  20. So AD, Gupta N, Brahmachari SK, Chopra I, Munos B, Nathan C, Outterson K, Paccaud JP, Payne DJ, Peeling RW, Spigelman M, Weigelt J. Towards new business models for R&D for novel antibiotics. Drug Resist Updat. 2011 Apr; 14(2):88-94. PMID: 21439891.
    View in: PubMed
  21. Kesselheim AS, Outterson K. Improving antibiotic markets for long-term sustainability. Yale J Health Policy Law Ethics. 2011; 11(1):101-67. PMID: 21381513.
    View in: PubMed
  22. Outterson K, Powers JH, Gould IM, Kesselheim AS. Questions about the 10 x '20 Initiative. Clin Infect Dis. 2010 Sep 15; 51(6):751-2; author reply 754-5. PMID: 20731566.
    View in: PubMed
  23. Kesselheim AS, Outterson K. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals. Health Aff (Millwood). 2010 Sep; 29(9):1689-96. PMID: 20820028.
    View in: PubMed
  24. Outterson K, Kesselheim AS. How Medicare could get better prices on prescription drugs. Health Aff (Millwood). 2009 Sep-Oct; 28(5):w832-41. PMID: 19643778.
    View in: PubMed
  25. Outterson K. Foreword--Will HPV vaccines prevent cervical cancers among poor women of color?: global health policy at the intersection of human rights and intellectual property law. Am J Law Med. 2009; 35(2-3):247-52. PMID: 19697748.
    View in: PubMed
  26. Outterson K. Introduction: pharmaceutical innovation: law & the public's health. J Law Med Ethics. 2009; 37(2):173-5. PMID: 19493064.
    View in: PubMed
  27. Outterson K, Kesselheim AS. Market-based licensing for HPV vaccines in developing countries. Health Aff (Millwood). 2008 Jan-Feb; 27(1):130-9. PMID: 18180488.
    View in: PubMed
  28. Outterson K. Should access to medicines and TRIPS flexibilities be limited to specific diseases? Am J Law Med. 2008; 34(2-3):279-301. PMID: 18697695.
    View in: PubMed
  29. Outterson K, Samora JB, Keller-Cuda K. Will longer antimicrobial patents improve global public health? Lancet Infect Dis. 2007 Aug; 7(8):559-66. PMID: 17646029.
    View in: PubMed
  30. Outterson K. Patent buy-outs for global disease innovations for low- and middle-income countries. Am J Law Med. 2006; 32(2-3):159-73. PMID: 16927608.
    View in: PubMed
  31. Outterson K. Pharmaceutical arbitrage: balancing access and innovation in international prescription drug markets. Yale J Health Policy Law Ethics. 2005; 5(1):193-291. PMID: 15742578.
    View in: PubMed
  32. Outterson K. Tragedy and remedy: reparations for disparities in black health. DePaul J Health Care Law. 2005; 9(1):735-91. PMID: 17061385.
    View in: PubMed
  33. Outterson K, Butler JL. Disease management: legal strategies for the next generation of managed care. J Health Law. 1998; 31(3):291-314. PMID: 10620832.
    View in: PubMed
Kevin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Similar BU People
_